<DOC>
	<DOCNO>NCT00036556</DOCNO>
	<brief_summary>This study do evaluate safety efficacy atrasentan men non-metastatic hormone-refractory prostate cancer .</brief_summary>
	<brief_title>Study Atrasentan Men With Non-Metastatic , Hormone-Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Atrasentan</mesh_term>
	<criteria>Have diagnose prostate cancer . Have rise PSA hormone therapy follow surgical castration . Have evidence distant metastatic disease screen bone scan CT scan . Have receive cytotoxic chemotherapy . Have receive opioid narcotic medication ( codeine morphine ) radiation pain cause prostate cancer last 6 month .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Hormone-Refractory Prostate Cancer</keyword>
</DOC>